Company intelligence / Profile preview

BioTronik Neuro

Lake Oswego, Oregon, United States

Ownership: Private
Development stage: Other

Overview

BIOTRONIK Neuro is the neuromodulation business segment of BIOTRONIK, a global leader in medical technology. Launched in 2023 following the FDA approval of its Prospera Spinal Cord Stimulation (SCS) system, the company focuses on treating chronic intractable pain of the trunk and limbs. Its core technology includes the RESONANCE multiphase stimulation paradigm and the Embrace One patient-centric care model, which features automatic, daily remote monitoring and proactive support. BIOTRONIK Neuro aims to improve long-term therapy success and reduce the service burden for clinicians and patients through its connected health solutions.

Therapeutic areas: RheumatologyNeurology
Modalities: Device
Industry: Therapeutic Medical Devices

Partnerships

University of Sydney

Beyond the preview

Go deeper on BioTronik Neuro.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioTronik Neuro.

Explore the full profile